TABLE 2.
Neurological signs and symptoms in patients treated with BV‐based regimens.
| Symptoms | Prospective cohort (N = 8) | Retrospective cohort (N = 12) | p |
|---|---|---|---|
| Paresthesia, n (%) | 7 (87.5) | 8 (66.7) | 0.6027 |
| Attenuated DTR, n (%) | 7 (87.5) | 6 (50%) | 0.1577 |
| Decreased tactile sensitivity, n (%) | 7 (87.5) | 4 (33.3) | 0.0281 |
| Neuropathic pain, n (%) | 3 (37.5) | 3 (25) | 0.6424 |
| Reduced vibratory sensitivity, n (%) | 5 (62.5) | 7 (58.3) | > 0.9999 |
| Impaired fine motor skills, n (%) | — | 8 (66.7) | > 0.9999 |
| Grade I neurological toxicity, n (%) | 1 (12.5) | 6 (50) | 0.1577 |
Abbreviations: BV, brentuximab‐vedotin; DTR, deep tendon reflexes.